Early reappearance of primary solid cancer in patients treated with purine analogs

Journal of Chemotherapy

Volumn 15, Issue 4, 2003, Pages 406-408

  Fazzi, R ^a   Caracciolo, F ^a   Galimberti, S ^a   Petrini, Mario ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b Department of Oncology   (Italy)

Author keywords

Chronic lymphatic leukemia; Indolent lymphoma; Metastasis; Purine analogs

Indexed keywords

ANTINEOPLASTIC AGENT; FLUDARABINE; FLUOROURACIL; IDARUBICIN; PREDNISONE; PURINE DERIVATIVE; STEROID;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; COLON ADENOCARCINOMA; FEMALE; HEMATOPOIETIC SYSTEM TUMOR; HERPES; HUMAN; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; LIVER METASTASIS; MALE; NONHODGKIN LYMPHOMA; SECOND CANCER; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0042848813     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.4.406     Document Type: Article

References (12)

1. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2:1067-9.
2. Zabay JM, De La Concha EG, Ludena C, et al. B-cell hyperactivity and abnormalities in T-cell markers and immunoregulatory function in a patient with nucleoside phosphorylase deficiency. Clin Exp Immunol 1982; 50: 610-6.
3. Giblett E, Amman A, Sandman R, Wara D, Diamond L. Nucleoside phosphorylase deficiency in a child with severely defective T cell immunity and normal B cell immunity. Lancett 1975; 1: 1010.
4. Ambrogi F, Petrini M, Carulli G, et al. Adenosine deaminase activity in human cord blood lymphocyte subpopulations. Cell Immunology 1982; 73: 404-9.
5. Goldschmidt-Clermont P, Petrini M, Khansari N, Fudenderg HH. The role of PNP in autologous rosette forming cells. Cell Immunology 1984; 87: 340-7.
6. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463-74.
7. Travis LB, Curtis RE, Glimelius B, et al. Second cancer among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932-7.
8. Anderson TC, Jones SE, Soehnlen BJ, Moon TE, Griffith K, Stanley P. Immunocompetence and malignant lymphoma: immunologic status before therapy. Cancer 1981; 48: 2072-9.
9. Ambrogi F, Polidori R, Azzarà A, Petrini M, Grassi B. Leucocyte migration inhibitory activity in the serum of patients affected by Hodgkin's disease and other Iimmunoproliferative diseases. Eur J Cancer 1978; 14: 1107-12.
10. Travis LB, Curtis RE, Boice Jr JD, Hankey BF, Fraumeni Jr JF. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67: 2002-9.
11. MacDougall B, Weinerman BH, Kemel S. Second malignancies in non-Hodgkin's lymphoma. Cancer 1981; 48: 1299-301.
12. Hemminki K, Jiang Y, Steieck G. Skin cancer and non-Hodgkin's lymphoma as second malignancies: markers of impaired immune function? Eur J Cancer 2003; 39: 223-9.